Thus, the presented data in the context of the current state of the art further indicate that the TGF-β signaling pathway has strong and critical impact on hepatocyte fate decisions that are directly related to liver diseases, including ASH, NASH, and HCC. This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatohepatitis.